Cadrenal Therapeutics (CVKD) Retained Earnings (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Retained Earnings of -$41.5 million for Q1 2026, down 199.42% sequentially from $41.7 million in Q4 2025, and down 40.21% YoY from -$69.3 million in Q1 2025.
Cadrenal Therapeutics (CVKD) Retained Earnings (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Retained Earnings for 5 years, with the latest figure at -$41.5 million in Q1 2026.
- Quarterly Retained Earnings fell 40.21% year-over-year to -$41.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.5 million (down 40.21% YoY) and the FY2025 annual result came in at $41.7 million, up 25.74% from the prior year.
- Retained Earnings retreated to -$41.5 million in Q1 2026 per CVKD's latest filing, from $41.7 million in the prior quarter.
- Over five years, Retained Earnings peaked at $41.7 million in Q4 2025 and troughed at -$41.5 million in Q1 2026.
- A 5-year average of -$2.5 million and a median of -$9.8 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings soared 439.02% in 2023, then slumped 243.91% in 2025.
- Over 5 years, Retained Earnings stood at -$6.7 million in 2022, then jumped by 439.02% to $22.8 million in 2023, then jumped by 45.68% to $33.2 million in 2024, then gained by 25.74% to $41.7 million in 2025, then slumped by 199.42% to -$41.5 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$41.5 million, $41.7 million, and -$35.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | 48.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.87 Mn |
| Mar 31, 2026 | -41.46 Mn |
| Dec 31, 2025 | 41.70 Mn |
| Sep 30, 2025 | -35.90 Mn |
| Jun 30, 2025 | -33.20 Mn |
| Mar 31, 2025 | -29.57 Mn |
| Dec 31, 2024 | 33.16 Mn |
| Sep 30, 2024 | 24.95 Mn |
| Jun 30, 2024 | -19.13 Mn |
| Mar 31, 2024 | -16.73 Mn |
| Dec 31, 2023 | 22.76 Mn |
| Sep 30, 2023 | 22.66 Mn |
| Jun 30, 2023 | -12.89 Mn |
| Mar 31, 2023 | 15.94 Mn |
| Dec 31, 2022 | -6.71 Mn |